These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
518 related articles for article (PubMed ID: 30280290)
21. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study. Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205 [TBL] [Abstract][Full Text] [Related]
22. Impact of primary tumor resection in the management of metastatic well-differentiated neuroendocrine tumors of the small bowel and pancreas. Russo A; DiPeri T; Dumitra T; Tseng J; Pletcher E; Justo M; Chen C; Nissen N; Amersi F; Gong J; Hendifar A; Gangi A J Neuroendocrinol; 2024 Aug; 36(8):e13399. PubMed ID: 38760997 [TBL] [Abstract][Full Text] [Related]
24. [Surgery for neuroendocrine tumors of the gastroenteropancreatic system (GEP-NET)]. Goretzki PE; Starke A; Akca A; Lammers BJ Internist (Berl); 2012 Feb; 53(2):152-60. PubMed ID: 22290318 [TBL] [Abstract][Full Text] [Related]
25. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors. Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616 [TBL] [Abstract][Full Text] [Related]
26. Fluorescence angiography guided resection of small bowel neuroendocrine neoplasms with mesenteric lymph node metastases. Kaçmaz E; Slooter MD; Nieveen van Dijkum EJM; Tanis PJ; Engelsman AF Eur J Surg Oncol; 2021 Jul; 47(7):1611-1615. PubMed ID: 33353827 [TBL] [Abstract][Full Text] [Related]
28. Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute. Shin Y; Ha SY; Hyeon J; Lee B; Lee J; Jang KT; Kim KM; Park YS; Park CK Cancer Res Treat; 2015 Oct; 47(4):738-46. PubMed ID: 25687852 [TBL] [Abstract][Full Text] [Related]
29. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas. Tang LH; Basturk O; Sue JJ; Klimstra DS Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015 [TBL] [Abstract][Full Text] [Related]
30. Surgical management of neuroendocrine tumors. Tamburrino D; Spoletini G; Partelli S; Muffatti F; Adamenko O; Crippa S; Falconi M Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):93-102. PubMed ID: 26971846 [TBL] [Abstract][Full Text] [Related]
31. Pretherapeutic evaluation of patients with upper gastrointestinal tract cancer using endoscopic and laparoscopic ultrasonography. Mortensen MB Dan Med J; 2012 Dec; 59(12):B4568. PubMed ID: 23290296 [TBL] [Abstract][Full Text] [Related]
32. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations. Russolillo N; Vigano' L; Razzore P; Langella S; Motta M; Bertuzzo F; Papotti M; Ferrero A Eur J Surg Oncol; 2015 Jun; 41(6):751-7. PubMed ID: 25887286 [TBL] [Abstract][Full Text] [Related]
33. Surgical Principles in the Management of Pancreatic Neuroendocrine Neoplasms. Andreasi V; Muffatti F; Guarneri G; Falconi M; Partelli S Curr Treat Options Oncol; 2020 Apr; 21(6):48. PubMed ID: 32350693 [TBL] [Abstract][Full Text] [Related]
34. Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms? Merola E; Rinke A; Partelli S; Gress TM; Andreasi V; Kollár A; Perren A; Christ E; Panzuto F; Pascher A; Jann H; Arsenic R; Cremer B; Kaemmerer D; Kump P; Lipp RW; Agaimy A; Wiedenmann B; Falconi M; Pavel ME Ann Surg Oncol; 2020 May; 27(5):1348-1355. PubMed ID: 31720931 [TBL] [Abstract][Full Text] [Related]
35. Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival. Keck KJ; Choi A; Maxwell JE; Li G; O'Dorisio TM; Breheny P; Bellizzi AM; Howe JR Ann Surg Oncol; 2017 Aug; 24(8):2206-2212. PubMed ID: 28560597 [TBL] [Abstract][Full Text] [Related]
36. Update in the Therapy of Advanced Neuroendocrine Tumors. Uri I; Avniel-Polak S; Gross DJ; Grozinsky-Glasberg S Curr Treat Options Oncol; 2017 Nov; 18(12):72. PubMed ID: 29143892 [TBL] [Abstract][Full Text] [Related]
37. Clinicopathological features and prognostic factors associated with gastroenteropancreatic mixed neuroendocrine non-neuroendocrine neoplasms in Chinese patients. Huang YC; Yang NN; Chen HC; Huang YL; Yan WT; Yang RX; Li N; Zhang S; Yang PP; Feng ZZ World J Gastroenterol; 2021 Feb; 27(7):624-640. PubMed ID: 33642833 [TBL] [Abstract][Full Text] [Related]
38. Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours. Gurusamy KS; Pamecha V; Sharma D; Davidson BR Cochrane Database Syst Rev; 2009 Jan; 2009(1):CD007118. PubMed ID: 19160322 [TBL] [Abstract][Full Text] [Related]
39. Presentation and survival of gastro-entero-pancreatic neuroendocrine tumors in young adults versus older patients. Nguyen AH; O'Leary MP; De Andrade JP; Ituarte PG; Warner SG; Melstrom LG; Kessler J; Fong Y; Li D; Singh G Am J Surg; 2022 May; 223(5):939-944. PubMed ID: 34474917 [TBL] [Abstract][Full Text] [Related]
40. Pediatric gastroenteropancreatic neuroendocrine tumor: A case report and review of the literature. Gaiani F; de'Angelis N; Minelli R; Kayali S; Carra MC; de'Angelis GL Medicine (Baltimore); 2019 Sep; 98(37):e17154. PubMed ID: 31517859 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]